Lupin receives tentative USFDA approval for Sitagliptin Tablets
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Express Scripts to add Zepbound to National Preferred Formulary
This product will be manufactured by Indoco Remedies at their manufacturing facility located at Goa
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Yesafili, received marketing authorization approval from the European Commission for the European Union
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Total transaction value of the divestment is Rs. 3,660 million
This product will be manufactured at Lupin’s Pithampur facility in India
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Subscribe To Our Newsletter & Stay Updated